Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivo-BeGEV in Relapsed/Refractory Hodgkin Lymphoma
NCT05660993Phase 2Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Aug 2019
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by National Medical Research Center for Hematology. Status: unknown.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05660993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660993.